Evidence map›Paper›PMID 40175935›Full record

ArticleBMC cardiovascular disorders2025

A case report on the implantation of a leadless pacemaker in a patient with eosinophilic fasciitis and third-degree atrioventricular block.

Li-Juan Huang, Jian-Shu Chen, Qi Zou, Yu-Zhe Song, Yi Yan, Zhao-Fen Wang, Hai-Juan Wang, Peng Chang

Abstract readCase Reports
In one paragraph

Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Li-Juan HuangLanzhou University, Lanzhou, 730030, China.
Jian-Shu ChenDepartment of Cardiology, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Qi ZouLanzhou University, Lanzhou, 730030, China.
Yu-Zhe SongLanzhou University, Lanzhou, 730030, China.
Yi YanLanzhou University, Lanzhou, 730030, China.
Zhao-Fen WangLanzhou University, Lanzhou, 730030, China.
Hai-Juan WangLanzhou University, Lanzhou, 730030, China.
Peng ChangDepartment of Cardiology, Lanzhou University Second Hospital, Lanzhou, 730030, China. pchang@lzu.edu.cn.

Funding

Cuiying Science and Technology Innovation Plan for Applied Basic Research at Lanzhou University Second Hospital CY2023-MS-B06Health and Wellness Research Project of Gansu GSWSQN2023-03Natural Science Foundation of Gansu 22JR5RA979
6 · The paper itself

Abstract

Eosinophilic fasciitis (EF) is a rare connective tissue disorder characterized by the involvement of the dermis, subcutaneous tissue, and fascia. The treatment for EF usually involves long-term use of glucocorticoids and immunosuppressants. Patients with EF are at risk of developing third-degree atrioventricular (AV) block during the course of the disease. The distinctive features of EF, the side effects of its treatment, and the inherent limitations of transvenous pacemakers (TVPs) present significant challenges in the management of patients with EF who also have third-degree AV block. We present the case of a 64-year-old Chinese male diagnosed with EF and concomitant third-degree AV block. Given the patient's skin tissue characteristics, the increased risk of infection associated with long-term immunosuppressive therapy, and the potential complications related to TVPs we chose to implant a leadless pacemaker(LP) in the apical region of the right ventricle. This case report underscores the importance of identifying potential cardiovascular complications in EF patients treated with corticosteroids and immunosuppressants. It also highlights the clinical benefit of LP implantation in managing patients with EF and third-degree AV block, especially in terms of minimizing device-related complications and infection risks. This study offers a fresh perspective on the treatment of EF patients who have third-degree AV block and advocates for the use of LPs as a preferred option for cardiac pacing in this patient group. Further research is warranted to evaluate the indications and potential benefits of LPs in a wider range of patients.

Indexed as

Atrioventricular BlockCardiac Pacing, ArtificialEosinophiliaFasciitisPacemaker, ArtificialHumansImmunosuppressive AgentsMaleMiddle AgedTreatment OutcomeImmunosuppressive AgentsCase reportEosinophilic fasciitisLeadless pacemakerMicraThird-degree atrioventricular block

Identifiers

PMID40175935
PMCPMC11963691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.